Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial

Ellis, Samuel L.; Moser, Emily; Snell‐Bergeon, Janet K.; Rodionova, A. S.; Hazenfield, R. M.; Garg, Satish K.

doi:10.1111/j.1464-5491.2011.03331.x

Cited by 118 publications

(101 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, mealrelated incretin (GLP-1 and GIP) responses are often diminished in type 2 diabetes [32] suggesting that different pathophysiological mechanisms are involved. In light of the recent development of GLP-1 analogues and dipeptidyl peptidase-IV inhibitors with glucagonostatic properties [31,33,34], add-on therapy combined with insulin could plausibly improve glycaemic control in patients with type 1 diabetes [35].…”

Section: Discussionmentioning

confidence: 99%

The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes

et al. 2014

View full text Add to dashboard Cite

Aims/hypothesis The influence of glucagon on glycaemic control in type 1 diabetes is debated. We investigated the relationship between postprandial glucagon levels and HbA 1c during a period up to 60 months after diagnosis of childhood type 1 diabetes. Methods The Danish remission phase cohort comprised 129 children (66 boys) with type 1 diabetes whose mean (SD) age at onset was 10.0 (3.9) years. Liquid mixed-meal tests were performed prospectively at 1, 3, 6 and 12 months and a subset of 40 patients completed follow-up at 60 months. Postprandial (90 min) plasma levels of glucagon, glucose (PG), C-peptide, total glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and HbA 1c were analysed. Multivariate regression (repeated measurements with all five visits included) was applied and results expressed as relative change (95% CI). Results Postprandial glucagon levels increased 160% from 1 to 60 months after diagnosis (p<0.0001). A doubling in postprandial PG corresponded to a 21% increase in postprandial glucagon levels (p=0.0079), whereas a doubling in total GLP-1 levels corresponded to a 33% increase in glucagon levels (p<0.0001). Postprandial glucagon associated negatively with postprandial C-peptide (p=0.017). A doubling in postprandial glucagon corresponded to a 3% relative increase in HbA 1c levels (p=0.0045). Conclusions/interpretation Postprandial glucagon levels were associated with deterioration of glycaemic control and declining beta cell function in the first 5 years after diagnosis of type 1 diabetes. The positive association of glucagon with total GLP-1 and PG suggests that physiological regulation of alpha cell secretion in type 1 diabetes is seriously disturbed.

show abstract

Section: Discussionmentioning

confidence: 99%

The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In T1DM, the effects of DDP-IV inhibitors as adjunct therapy to insulin have been investigated in small, short-term studies. Twenty patients with T1DM participated in an 8 weeks double-blinded, randomized study in which subjects received sitagliptin 100 mg/day or placebo for 4 weeks and then crossed over [72]. Sitagliptin significantly reduced prandial insulin requirements and glucose levels (as measured by continuous glucose monitoring).…”

Section: Ddp-iv Inhibitorsmentioning

confidence: 99%

Management of Severe Insulin Resistance in Patients with Type 1 Diabetes

Schechter¹,

Reutrakul

2015

Curr Diab Rep

View full text Add to dashboard Cite

Managing severe insulin resistance (IR) in patients with type 1 diabetes (T1DM) can be challenging for both clinicians and patients. As average weight for patients with T1DM has increased in recent decades, IR in this population has become more widespread. Currently, almost 50 % of patients with T1DM are overweight or obese. While intensive insulin therapy is associated with reduction in complications, aggressive treatment can lead to weight gain. With increasing weight, insulin can become less effective to control glycemia, resulting in higher insulin doses and hence more weight gain. Novel strategies to break this vicious cycle are needed. This review will investigate current research on insulin formulations, lifestyle modification, adjunct therapies, and surgery that may help better manage patients with T1DM and IR.

show abstract

“…Jednakże również badanie Ellis i wsp. wykazało korzystny wpływ sitagliptyny na redukcję stężenia glukozy we krwi, zarówno wartości poposiłkowej, jak i ocenianej w profilu dobowym u pacjentów z cukrzycą typu 1 [21].…”

Section: Leki Z Grupy Inkretyn W Terapii Cukrzycy Typuunclassified

Czy leki inkretynowe i inhibitory SGLT-2 mogą znaleźć zastosowanie w leczeniu cukrzycy typu 1?

Różańska¹,

Wierusz‐Wysocka

Zozulińska‐Ziółkiewicz

2015

Diabetologia Kliniczna

View full text Add to dashboard Cite

Cukrzyca obecnie jest zaliczana do heterogennej grupy chorób metabolicznych, których wspólną cechą jest hiperglikemia. Rozwija się ona w następstwie zaburzeń czynności wydzielniczej komórek beta wysp trzustki prowadzących do zmniejszenia sekrecji insuliny. Inną przyczyną schorzenia może być zmniejszenie lub brak wrażliwości komórek mięśniowych, tkanki tłuszczowej i wątroby na działanie tego hormonu. Cukrzyca należy do najczęstszych chorób przewlekłych współczesnej cywilizacji. W Polsce u ponad 2 mln ludzi rozpoznano cukrzycę, w tym u około 250 tys. cukrzycę typu 1. Leczenie zaburzeń gospodarki węglowodanowej stanowi jeden z najważniejszych problemów współczesnej medycyny. Wyniki badania United Kingdom Prospective Diabetes Study (UKPDS) wykazały, że dobra kontrola metaboliczna cukrzycy typu 2 (HbA 1c < 7%) od początku choroby jest w stanie zmniejszyć częstość występowania groź-nych dla życia powikłań mikro-i makroangiopatycznych (miażdżycowych) [1]. Uzyskane w tym zakresie wyniki są jednak nadal niezadowalające, ponieważ choroba jest rozpoznawana zbyt późno, naturalna jest jej stopniowa progresja, a stosowane leki, chociaż skuteczne na początku choroby, w okresie późniejszym nie zabezpie-

show abstract

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial

Cited by 118 publications

References 16 publications

The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes

The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes

Management of Severe Insulin Resistance in Patients with Type 1 Diabetes

Czy leki inkretynowe i inhibitory SGLT-2 mogą znaleźć zastosowanie w leczeniu cukrzycy typu 1?

Contact Info

Product

Resources

About